Recent Updates
Recently added Catalysts
SNTI Neutral Sentiment

Engineered IMiD Regulated Synthetic Transcriptional Switch for Controlled and Dose-Responsive Expression of Therapeutic Payload within FDA-Approved Drug Doses

Wednesday, May 15, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a presentation at the ASGCT Annual Meeting regarding an engineered IMiD regulated synthetic transcriptional switch. This technology aims to enable controlled and dose-responsive expression of therapeutic payloads within FDA-approved drug doses. The details of the research and its implications were presented by a team of researchers.
Price reaction · baseline $3.71 (2024-05-15T13:36:00.000Z) · hit during market hours · 1 other SNTI headline(s) in the window, move may be shared
day 0 close · peak
+1.9%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
76.7%
average across 4 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
SENTI-202
Phase 1 · AML/MDS

Full Press Release Details

ASGCT Annual Meeting Rebecca Cottman, Myles MacEachern, Michelle Hung, Andrew Banicki, Mengxi Tian, Chen-Ting Lee, Assen Roguev, Chew-Li Soh, Conor McAuliffe, Mark Tomishima, Raghav Kannan, Chandra Verma, Timothy K. Lu, Russell Gordley, Philip Lee

View PDF

ShareAdd on Google
Tags: SNTI Viatris Investor Conferences Healthcare ASGCT therapeutic payload synthetic switch FDA-approved
Last updated: May 15, 2024

Biotech snapshot

Cash runway
$19M liquidity · $2M/mo burn
~5 mo
High dilution risk
Lead asset
SENTI-202Phase 1
AML/MDS →

Catalyst track record

+84%
best trade around SNTI's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SNTI.

See every catalyst's timing & PoA →